Pluristem granted approval to test placenta cell-based therapy in Israel

10/4/2013 | Pharmaceutical Business Review Online

Pluristem Therapeutics obtained clearance from the Israeli Ministry of Health to initiate a midstage trial of its PLacental eXpanded cells in patients with intermittent claudication. The trial in Israel will follow the same protocol used by Pluristem in its U.S. study, which involved around 150 patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD